choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Arzerra

Arzerra Newsletter
  • Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight 12 May 2025 17:00 GMT

    medicine is transforming treatment … RITUXAN, ARZERRA, and … trials. Pharmaceutical companies are actively pursuing innovative treatmentsdrugs in development @ Chronic Lymphocytic Leukemia Clinical Trials Chronic Myeloid Leukemia Market Chronic myeloid leukemia

  • Betaseron interactions: Alcohol, medications, and other factors 28 Feb 2025 14:06 GMT

    medications together. Examples of HIV drugs: Here are some HIV drugs … ofatumumab (Arzerra, Kesimpta) Steps you or your doctor may take … treatment with Betaseron, talk with your doctor. Betaseron and vaccines … t been enough clinical trials to determine whether …

  • Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery 01 Oct 2024 05:24 GMT

    … of nanomedicine and biotechnology holds promise … -Drug Conjugates Using Cysteine Insertion. Mol Pharmaceut. … Medicines Agency review of ofatumumab (Arzerra(R)) for the treatment of chronic lymphocytic leukemia … Du L. Subunit Vaccines Against Emerging Pathogenic …

  • New Drug Therapy Approvals 2020 17 Jun 2024 18:46 GMT

    medication that is taken as a single dose in pill … agreed to with the pharmaceutical industry and approved by … name, Arzerra—to treat certain patients with chronic lymphocytic leukemia. Its … is the first drug treatment approved by the FDA for mesothelioma in …

  • Chronic Lymphocytic Leukemia Market Forecast 2032: FDA Approvals, Clinical Trials, Drugs and Companies, by DelveInsight 18 Jun 2024 14:01 GMT

    … , MingSight Pharmaceuticals, Nurix … drug. Chronic Lymphocytic Leukemia Drugs Uptake helps in understanding the drugsLeukemia Clinical Trials and FDA Approvals Chronic Lymphocytic LeukemiaLeukemia Treatment Algorithm, Current Treatment, and Medical

  • 9 biotech companies leading the way in Denmark 26 Mar 2024 18:36 GMT

    medical need for a vaccine against … with biotechnology and pharmaceutical companies, … treatment of multiple myeloma, Arzerra (ofatumumab), which is indicated for chronic lymphocytic leukemiatreatment with certain chemotherapy drugs. IO Biotech IO Biotech

  • Arzerra dosage 08 Mar 2024 16:04 GMT

    … name drug prescribed for chronic lymphocytic leukemia (CLL) in some adults. Arzerra comes … severity. Arzerra is approved by the Food and Drug Administration (FDA) for … Doctors may prescribe Arzerra as a first treatment for CLL if fludarabine-based medications

  • Bexsero interactions: Alcohol, medications, and other factors 10 Jan 2024 18:24 GMT

    … receiving Bexsero, tell your doctor about other medications you take. They’ll … treatment may weaken your immune system. Receiving Bexsero while taking this drugdoctor before receiving this vaccine. Pregnancy: There haven’t been enough clinical trials

  • 3 Biotech Companies to Watch in 2023 07 Jan 2023 00:33 GMT

    … and precision medicine, biotech companies have … drug design. Offering some of the most revolutionary medicinestreatments for some of the world’s greatest medical challenges, Vertex Pharmaceuticals … cancer, while Arzerra tackles leukemia and multiple …

  • Global Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic 16 Sep 2022 10:30 GMT

    … Hematological Malignancies Drugs Market- by Drugs (Monoclonal … (Brentuximab Vedotin), Arzerra (Ofatumumab), CAR-T … treatment of various types of hematological malignancies, and growing advancements in leukemia … S.A., Takeda Pharmaceutical Company Limited, …

Satisfied with the content?

Continue to create your account.